Chemical sulfonation and anticoagulant activity of acharan sulfate

Thrombosis Research

Volumn 92, Issue 6, 1998, Pages 273-281

  Wu, Song Ji ^a   Chun, Moon Woo ^a   Shin, Kuk Hyun ^a   Toida, Toshihiko ^b   Park, Youmie ^c   Linhardt, Robert J ^c   Kim, Yeong Shik ^a  

^a Seoul National University   (South Korea)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Acharan sulfate; Anticoagulant activity; Chemical N sulfonation

Indexed keywords

ACHARAN SULFATE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CHEMICAL MODIFICATION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTICOAGULANTS; GLYCOSAMINOGLYCANS; HEPARIN; SNAILS; SULFONES;

EID: 0032535464     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00146-7     Document Type: Article

References (26)

1. 1. Hardingham TE, Fosang AJ. Proteoglycans: Many forms and many functions. FASEB J 1992;6:861-70.
2. 2. Kjellen L, Lindahl U. Proteoglycans: Structures and interactions. Ann Rev Biochem 1991;60: 443-75.
3. 3. Jolles P. Proteoglycans. Basel: Birkhauser; 1994.
4. 4. Lane DA, Lindahl U. Heparin. Chemical and Biological Properties, Clinical Applications, Boca Raton: CRC Press; 1989.
5. 5. Harenberg J, Casu B. Nonanticoagulant Actions of Glycosaminoglycans. New York: Plenum Press; 1996.
6. 6. Linhardt RJ, Toida T. Heparin analogues-development and applications. In: Witczak ZB, Nieforth KA, editors. Carbohydrates as Drugs. New York: Marcel Dekker; 1997. p. 277-341.
7. 7. Kim YS, Jo YY, Chang IM, Toida T, Park YM, Linhardt RJ. A new glycosaminoglycan from African giant snail Achatina fulica. J Biol Chem 1996;27:11750-5.
8. 8. Wang H, Toida T, Kim YS, Capila I, Hileman RE, Bernfield M, Linhardt RJ. Glycosaminoglycans can influence growth factor-2 mitogenecity without significant growth factor binding. Biochem Biophy Res Commun 1997;235: 369-73.
9. 9. Taylor KA, Bucanan-Smith JG. A colorimetric method for the quantitation of uronic acid and a specific assay for galacturonic acid. Anal Biochem 1992;201:190-6.
10. 10. Silvestri LJ, Hurst RE, Simpson L, Settine J. Analysis of sulfate in complex carbohydrate Anal Biochem 1982;123:303-9.
11. 11. Shaklee PN, Conrad HE. Hydrazinolysis of heparin and other glycosaminoglycans. Biochem J 1984;217:187-97.
12. 12. Nadkarni VD, Toida T, Van Gorp CL, Schubert RL, Weiler JM, Hansen KP, Caldwell EEO, Linhardt RJ. Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives. Carbohydr Res 1996; 290:87-96.
13. 13. Doctor VM, Sauls V. Isolation and anticoagulant properties of a new sulfated xylan: Comparison with heparin and a sodium pentosan polysulfate (SP-54). Thromb Res 1983;30:573-8.
14. 14. Linhardt RJ, Rice KG, Kim YS, Lohse DL, Wang HM, Loganathan L. Mapping and quantification of the major oligosaccharide components of heparin. Biochem J 1988;254:781-7.
15. 15. Linhardt RJ. Analysis of glycosaminoglycans with polysaccharide lyases. Varki A, editor. Current Protocols in Molecular Biology. Boston: Wiley Interscience; 1994. p. 17.13.17-32.
16. 16. Scully MF, Ellis V, Seno N, Kakar VV. Effect of oversulfated chondroitin and dermatan sulfate upon thrombin and factor inactivation by antithrombin III or heparin cofactor II. Biochem J 1988;254:547-51.
17. 17. Maaroufi RM, Tapon-Bretaudiere J, Mardiguian J, Sternberg C, Dautzenberg MD, Fischer AM. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives. Thromb Res 1990;59:749-58.
18. 18. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, Oreste P, Tursi F, Zoppetti G, Lindahl U. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res 1994; 263:271-84.
19. 19. Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985; 43:51-134.
20. 20. Lane AD, Denton J, Flynn AD, Thunburg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984;218:725-32.
21. 21. Lindahl U, Backström B, Thunberg L, Leder IG. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980;77: 6551-5.
22. 22. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983;258:6713-6.
23. 23. Linhardt RJ, Hileman RE. Dermatan sulfate as a potential therapeutic agent. Gen Pharmacol 1995;26:1609-91.
24. 24. Nagase H, Eniyoji K, Minamiguchi K, Kitazato K, Saito H, Kato H. Depolymerized halothrium glycosaminoglycan with novel anticoagulant actions: Antithrombin III-and heparin cofactor II-independent inhibition of factor X activation by factor IXa-Factor Villa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995;85:1527-34.
25. 25. Maaroufi RM, Jozefowicz M, T.-Bretaudiere J, Fisher AM. Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin. Biomaterials 1997;4:359-66.
26. 26. Dace R, McBride E, Brooks K, Gander J, Buszko M, Doctor VM. Comparison of the anticoagulant action of sulfated and phosphorylated polysaccharides. Thromb Res 1997;87:113-21.